#### **CASE SERIES**

## **TITLE**

1

2 3 4

5

6

7 8 9

17 18

19

43

Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series.

# **AUTHOR NAMES AND AFFILIATIONS**

- 10
- Xavier Solanich, MD<sup>1,†,\*</sup>, Gardenia Vargas-Parra, MD, PhD<sup>2,3,†</sup> Caspar I. van der Made<sup>4-7,†</sup>, Annet Simons<sup>4</sup>, Janneke Schuurs-Hoeijmakers<sup>4</sup>, Arnau Antolí, MD<sup>1</sup>, Jesús 11
- del Valle, PhD<sup>2,3</sup>, Gemma Rocamora-Blanch, MD<sup>1</sup>, Fernando Setién, PhD<sup>8</sup>, Manel 12
- Esteller, MD, PhD<sup>3,8-10</sup>, Antoni Riera-Mestre, MD, PhD<sup>1,11</sup>, Joan Sabater-Riera, MD, 13
- 14
- PhD<sup>12</sup>, Gabriel Capellá, MD, PhD<sup>2,3</sup>, Frank L. van de Veerdonk<sup>5-7</sup>, Ben van der Hoven<sup>13</sup>, Xavier Corbella, MD, PhD<sup>1,14</sup>, Alexander Hoischen<sup>4-7,\*</sup> and Conxi Lázaro, PhD<sup>2,3,\*</sup> 15
- 16
  - <sup>1</sup> Department of Medicina Interna. Hospital Universitari de Bellvitge IDIBELL.
- 20 L'Hospitalet de Llobregat, Barcelona, Spain
- 21 <sup>2</sup> Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular
- 22 Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL,
- 23 L'Hospitalet de Llobregat, Barcelona, Spain
- <sup>3</sup> Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 24
- 25 <sup>4</sup> Department of Human Genetics, Radboud University Medical Center, Nijmegen, the 26 Netherlands
- 27 <sup>5</sup> Radboud University Medical Center Center for Infectious Diseases (RCI), Department
- of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands 28
- 29 <sup>6</sup> Radboud Institute for Molecular Life Sciences, Radboud University Medical Center,
- 30 Nijmegen, the Netherlands
- 31 <sup>7</sup> Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud
- 32 Center for Infectious Disease (RCI), Radboud University Medical Center, Nijmegen, 33 the Netherlands
- <sup>8</sup> Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain 34
- <sup>9</sup> Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain 35
- 36 <sup>10</sup>Physiological Sciences Department, School of Medicine and Health Sciences,
- 37 University of Barcelona (UB), Barcelona, Spain
- <sup>11</sup> Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain 38
- <sup>12</sup> Department of intensive Care. Hospital Universitari de Bellvitge IDIBELL. 39
- 40 L'Hospitalet de Llobregat, Barcelona, Spain
- <sup>13</sup> Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands 41
- <sup>14</sup> School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. 42
- <sup>†</sup> These authors contributed equally and should be considered first co-authors 44
- \*These three authors should be considered senior and corresponding authors 45

46 **CORRESPONDING AUTHOR** 47 Xavier Solanich, MD 48 Department of Internal Medicine, 49 Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL) 50 Feixa Llarga sn. 08907 L'Hospitalet de Llobregat (Barcelona), Spain 51 Phone: 0034 96 260 2324 52 Fax: (+34) 93 260 7967 53 Email: xsolanich@bellvitgehospital.cat 54 55 56 Alexander Hoischen 57 Departments of Human Genetics and Internal Medicine 58 Radboud University Medical Center 59 Nijmegen, the Netherlands 60 Phone: (+31) 24 3619639 61 Email: Alexander.Hoischen@radboudumc.nl 62 63 64 Conxi Lázaro, Ph.D. 65 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC. 66 67 Av. Gran Via 199-203. 08908 Hospitalet de Llobregat (Barcelona), Spain. 68 Phone: (+34) 93 2607145 69 E-mail: clazaro@iconcologia.net 70 71 72

# **KEYWORDS**

- 73 COVID-19; SARS-CoV-2; host genetics; TLR7; immunodeficiency; rare variants;
- 74 genetic screening

# **ABSTRACT**

75

76

77

78

79

80

81

82

83

84

85

86

87

88 89

90

91

92

93

94

95

96

97

98

99

100 101

102

Advanced age, male sex and chronic comorbidities are associated with severe COVID-19. However, these general risk factors cannot explain why critical illness occurs in young and apparently healthy individuals. In the past months, several publications have identified susceptibility loci and genes using comprehensive GWAS studies or genome, exome or candidate genes analysis. A recent study reported rare, loss-of-function TLR7 variants in otherwise healthy young brother pairs from two families with severe COVID-19. We aimed to prospectively study the prevalence of rare X-chromosomal TLR7 genetic variants in our cohort of young male patients with severe COVID-19. We recruited 13 patients ≤50 years who had no risk factors known to be associated with severe disease. We studied the entire TLR7 coding region and identified two missense variants (p.Asn215Ser, c.644A>G and p.Trp933Arg, c.2797T>C) in two out of 13 cases (15.4%). These variants were not previously reported in population control databases (gnomAD) and were predicted to be damaging by all in silico predictors. The male index patients were between 25 and 30 years old and had no apparent comorbidities. The TLR7 p.Asn215Ser co-segregated in 2 first-degree relatives severely affected by COVID-19, in a younger previously healthy the variant was found in hemizygous state, and in an older than 60 was in heterozygous state. No family members were available for testing the segregation of the p.Trp933Arg variant. These results further support that susceptibility to severe COVID-19 could be determined by inherited rare genetic variants in TLR7. Understanding the causes and mechanisms of life-threatening COVID-19 is crucial and could lead to novel preventive and therapeutic options. This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors. A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but it also enables for pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions.

#### INTRODUCTION

103

- A proportion of patients with COVID-19 evolve to fatal lung injury and multi-organ 104
- 105 failure due to systemic host-immune inflammatory processes triggered by the viral
- 106 infection [1]. Advanced age, male sex and chronic disease such as diabetes and obesity
- 107 are common in patients with more severe forms of COVID-19 [2-4]. However, these
- 108 risk factors cannot explain why critical disease also occurs in younger (below 50 years
- 109 of age) and apparently healthy individuals.
- 110 In the past months, several publications identified susceptibility loci and genes using
- 111 comprehensive GWAS studies or genome, exome or candidate genes analysis. Hence,
- 112 human genetic loci associated with a higher viral binding and entry comprised the ABO
- 113 blood group locus [5-7], ACE2 and TMPRSS2 [8]. Genetic loci reported to predispose to
- 114 higher severity include the 3p21.31 gene cluster [5], HLA-B\*46:01 and HLA-B\*15:03
- 115 [9], APOE [10], IFITM3 [11], as well as several genes encoding for members of the
- 116 type I/III interferon (IFN) pathway [12] including the Toll-Like Receptor 7 (TLR7) gene
- 117 [13]. The Barcelona research group collaborated with a large genetic sequencing effort
- 118 to define host risk factors to severe SARS-CoV-2 infection, analyzing exome or genome
- 119 sequences from 659 patients with severe COVID-19 for rare pathogenic variants that
- 120 could be associated with life-threatening disease [12]. This collaborative study was
- 121 focused on the type I IFN pathway and analyzed 13 candidate genes (TLR3, IRF7, IRF9,
- 122 TICAM1/TRIF, UNC93B1, TRAF3, TBK1, IRF3, NEMO/IKBKG, IFNAR1, IFNAR2,
- 123 STAT1 and STAT2) that have previously been linked with susceptibility to other viral
- 124 infections. Loss of function variants were identified in 3.5% (23/659) of cases. In
- 125 addition, a study of 156 Italian and Spanish <60 year-old patients with severe COVID-
- 126 19, TLR7 rare, but not entirely unique, missense variants were found in almost 4% and
- 127 in none of the 122 oligo- or asymptomatic controls. Expression profiles of TLR7 and
- 128 type 1 IFN-related genes were studied in imiquimod-treated-PBMCs carrying 4
- 129 different variants (p.(Val219Ile), p.(Ser301Pro), p.(Ala1032Thr), p.(His630Tyr)) and
- the authors found a significant decrease of IRF7 and IFN-y mRNA levels compared 130
- 131 with healthy controls [Fallerini, preprint medRxiv 2020].
- Here we describe two index patients with rare, putatively deleterious germline variants 132
- 133 in the X-chromosomal TLR7 gene. This finding reinforces the notion that TLR7 plays a
- 134 critical role in the recognition of SARS-CoV-2 and the initiation of an early immune
- 135 response to clear the virus and prevent the development of severe COVID-19. Our
- 136 findings furthermore support the idea that, in some male patients, severe COVID-19
- 137 could be determined by rare TLR7 variants and genetic screening may be appropriate in
- 138 young, severely affected men without comorbidities predisposing to severe disease.

# METHODS AND RESULTS

- 141 This is a joint study performed at the Hospital Universitari de Bellvitge – IDIBELL,
- 142 L'Hospitalet de Llobregat, Barcelona, Spain; and the Radboud University Medical
- 143 Center, Nijmegen, The Netherlands and the Erasmus Medical Center, Rotterdam, The
- 144 Netherlands.

- 145 The Barcelona cases
- 146 From March to July 2020, researchers from Hospital Universitari de Bellvitge -
- 147 IDIBELL prospectively collected biological samples from young patients without
- 148 comorbidities related with severe COVID-19. Selection criteria were: 1) patients aged
- 149 between 18 and 50 years old; 2) absence of known comorbidities associated with most

- 150 severe forms of COVID-19; and 3) SARS-CoV-2 related lung injury requiring high
- 151 flow oxygen devices or mechanical ventilation. Ten male patients fulfilled all selection
- 152 criteria (Table 1). Eight patients (patients 1-8) were evaluated also by the COVID
- 153 Human Genetic Effort where no pathogenic variants were detected in any of the 13 type
- 154 I IFN pathway genes studied [12], none of those eight Barcelona patients carried a rare
- 155 TLR7 variant.
- 156 Informed consent was obtained from all patients and relatives, and the IDIBELL
- 157 Research Ethics Committee approved this study (PR152/20). Demographic,
- 158 epidemiological, laboratory and clinical data were collected. Treatments specifically
- 159 used to treat COVID-19 at any time during admission were also documented.
- 160 DNA was isolated from total blood either using a Maxwell instrument RSC (Promega,
- 161 Madison, WI, USA) or QIAGEN Flexigene DNA kit (Qiagen, Germany). Nine PCR
- 162 primer pairs (Sigma-Aldrich, MO, USA) were designed to cover the whole coding
- 163 region of TLR7 gene. PCR was performed using DreamTaq MasterMix (ThermoFisher
- 164 Scientific, Waltham, MA, USA), products were purified using EXO-SAP (New
- 165 England Biolabs) and sequenced using the BigDye Terminator v.3.1 Sequencing Kit
- (Applied Biosystems, CA, USA) in an ABI Prism 3730 XL Genetic Analyzer (Applied 166
- 167 Biosystems CA, USA). Primers and PCR conditions were available upon request.
- 168 Mutation Surveyor software was used to detect variants and nomenclature was given
- 169 according to HGVS guidelines. All variants identified were submitted to Alamut
- 170 Software Suite v2.15.0 (Interactive Biosoftware) to retrieve population frequency and in
- 171 silico prediction data.
- 172 The Dutch cases
- 173 At the Radboud University Medical Center in Nijmegen and the Erasmus Medical
- 174 Center in Rotterdam, the Netherlands, patients were screened prospectively in a clinical
- 175 setting prospectively from December 2020 to February 2021 with the following criteria:
- 176 1) males aged below 40 years of age; 2) absence of comorbidities known to be
- 177 associated with severe COVID-19 and 3) PCR-confirmed SARS-CoV-2 infection
- 178 requiring high-flow oxygen therapy or ICU admission. A total of 3 patients (patients 11-
- 179 13) fulfilled these inclusion criteria and underwent clinical Sanger sequencing (patient
- 180 11 and 12) or rapid whole-exome sequencing (patient 13) to specifically assess genetic
- 181 variants in TLR7. Written informed consent was also obtained from patient 13 whose
- 182 clinical data has been included in this study. Rapid whole-exome sequencing was
- 183 performed similar to previous reports [13]. Sanger sequencing was done according to
- 184 standard diagnostic procedures at the Department of Human Genetics, Radboud
- 185 University Medical Center, protocols and primers sequences are available upon request.

# **TLR7** Sequencing Results

- 187 A total of 13 patients were included, with an average age of 37.85 (SD 9.026) years old.
- 188 Putative deleterious TLR7 variants were identified in two patients (patient 10 and 13).
- 189 Both variants, which included a TLR7 c.644A>G, p.(Asn215Ser) missense variant in
- 190 patient 10 and a c.2797T>C p.(Trp933Arg) missense variant in patient 13, were not
- 191 previously reported in our in-house database nor in the population database gnomAD
- 192 [14]. Moreover, the Asn215Ser variant affects a highly conserved nucleotide and amino
- 193 acid in the TLR7 leucine-rich region domain and it is predicted damaging or possibly
- 194 damaging by in silico software. The Trp933Arg variant is also located at an
- 195 evolutionarily highly conserved position within the TIR domain, important for
- 196 downstream signaling via adapter proteins, and is considered deleterious by the in silico

197 effect predictors. These variants and other previously reported variants in COVID-19

198 patients are shown schematically in Figure 1.

# TLR7 patients' characteristics

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226 227

228

229

230

236 237 Patient 10 was of Latin origin man in his 30s with no general risk factors predisposing to severe COVID-19. He developed pneumonia with bilateral consolidations on a computed tomography (CT) scan and fulfilled the criteria of acute respiratory distress syndrome (ARDS) secondary to PCR-proven COVID-19 (Table 2). The patient received antiviral treatment with remdesivir and immunosuppressive therapy with dexamethasone. Due to respiratory insufficiency, the patient was intubated and admitted at the ICU. The patient could be successfully extubated after 4 days of mechanical ventilation support and was discharged from ICU after 6 days. After the identification of the TLR7 c.644A>G variant in the patient, segregation analysis confirmed segregation in both 2 first-degree relatives. The younger relative (<30 years)was previously healthy without any comorbidity but, similarly to the index case, also contracted severe COVID-19, requiring mechanical ventilation and ICU admission at another hospital (Table 2). The brother pair of this family therefore represents the third pair of brothers with severe COVID-19, following the initial report [13]. Their older than 60 years relative suffered from obesity, dyslipidemia, type 2 diabetes and hypertension, and was also admitted at ICU due to critical respiratory failure caused by COVID-19. She was discharged from the ICU 16 days after admission. Main demographic, clinical, laboratory, and radiological findings of the three relatives are summarized in Table 2.

Patient 13 was a Caucasian male in his 20s without previous medical history or comorbidities. The patient complained of progressive dyspnea and shortness of breath and due to rapid clinical deterioration and respiratory insufficiency, he was intubated by the medical emergency team at his home and subsequently hospitalized in ICU at a peripheral hospital. A CT-scan showed multiple diffuse ground-glass opacities and consolidations in all lung segments, meeting the criteria for ARDS. Treatment consisted of mechanical ventilation with prone positioning, intravenous dexamethasone, and the antibiotics ceftriaxone and ciprofloxacin. However, the patient's condition further deteriorated and he was referred to the Erasmus Medical Center for possible ECMO treatment. However, with continuing prone positioning he gradually improved before ECMO was required. A repeated CT scan also showed subsegmental pulmonary embolisms for which intravenous heparin was started. In the following weeks, the patient gradually recovered and to date remains in the ICU after a total of 26 days. He

231 232 has started physical therapy and is weaning of the ventilator.

233 The patients' whole family contracted COVID-19 at the time the patient developed

234 symptoms, including his brother, who had only minor symptoms. Variant segregation

235 analysis is still pending.

#### **DISCUSSION**

- 238 In July 2020, rare, deleterious, germline variants in the X-chromosomal TLR7 gene
- 239 were reported in young and, otherwise, healthy males with severe COVID-19. In these
- 240 two brother pairs, rapid whole-exome sequencing identified both a maternally inherited
- 241 4-nucleotide deletion (c.2129\_2132del; p.(Gln710Argfs\*18)) and a missense variant
- 242 (c.2383G>T; p.(Val795Phe)). Both variants were associated with impaired type I and II
- 243 IFN responses, showing its importance in the COVID-19 pathogenesis [13].

244 Since TLR7 was not one of the genes initially evaluated by the COVID Human Genetic 245 Effort, our Barcelona team decided to perform a TLR7 Sanger sequencing analysis in 246 their case series consisting of 10 healthy young males with severe COVID-19. We 247 identified one patient with a new missense variant (c.644A>G; p.(Asn215Ser)) labelled 248 as damaging by in silico predictors. In addition, three Dutch cases were added to this 249 series who underwent genetic screening in a clinical setting, leading to the identification 250 of another novel, unique missense variant (c.2797T>C; p.(Trp933Arg)) located in the

251 highly conserved TIR domain. While we cannot unequivocally prove the pathogenicity

252 of the variants identified, the odds of identifying two private missense variants in just 13 253

cases is very unlikely a chance finding, considering the extremely rare prevalence of

254 TLR7 variants in gnomAD.

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

282

283

284

285

286

287

288

289

290

291

292

The finding of these two variants in a total of 13 screened patients (15.4%) led us to consider that TLR7 variants could be a relatively common cause predisposing to severe COVID-19 in this subset of young, male patients with absence of general risk factors for severe disease. However, it should be noted that complete TLR7 deficiency is estimated to be extremely rare. Endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) have evolved under strong purifying selection. This selective regime ensures the conservation of particularly important proteins and indicates that these receptors play an essential, non-redundant biological role in host survival [15-16]. Therefore, rare TLR7 non-synonymous variants are unlikely to be an explanation for severe COVID-19 in the general population. It is intriguing to speculate that some, very rare variants compromising essential functional domains in TLR7 lead to a complete deficiency [13], while other, relatively less rare variants may lead only to a partial TLR7 deficiency, and therefore may impact a larger group of individuals, but exert a lower relative risk to develop severe COVID-19. It is therefore interesting, that these latter variants have been also be identified in individuals of elevated age and also compromise TLR7 function [Fallerini, preprint MedRxiv 2020].

271 Common low effect size genetic variants in TLR7 have been proposed as a possible 272 explanation of the male sex bias in COVID-19 severity because of its localization on the 273 X chromosome and well-established function in innate immunity [17]. Interestingly, 274 circulating 25-hydroxy vitamin D (250HD) levels decline with age [18] and may be 275 accompanied by a lower expression and defective function of TLR7 [19]. Accordingly, 276 TLR7 function could be modified by genetic but also epidemiological factors and 277 certain comorbidities. So it is possible, but only speculative, that the addition of several 278 factors that modify TLR7 function may be a common cause of progression to the most 279 severe stages of COVID-19 in male. The same speculative hypothesis could be 280 applicable to other genes involved in immune response regulation after SARS-CoV-2 281 infection [4,20].

Specific genetic variants that confer a higher risk to biological agents such as HIV, malaria and tuberculosis have been identified through NGS and genome wide association studies (GWAS) [21]. These host DNA variants now serve as biomarkers that can be used for early diagnosis and prophylaxis, and allow the identification of possible molecular targets for treatment. This also applies to susceptibility to SARS-CoV-2 that could be determined by genes related to viral binding and entry, as well as genes related with immune response to the SARS-CoV-2 [4]. The small cohort study presented here, with an unexpectedly high yield (2/13) encourages that a screen for TLR7 rare variants in severely affected men may be useful. While also elderly individuals may carry rare TLR7 variants those individuals may be more difficult to identify; we therefore suggest the following preliminary screening criteria: young men

293 (<50 year of age); previously healthy; suffering from severe COVID-19 in addition

294 affected young brother pairs – as well as pedigrees suggestive for X-linked segregation -

should be further prioritized.

305

306

307

308

309

310

311

312

313

314

296 Unfortunately, there is still a paucity of therapies that has been proven effective and safe

in the treatment of COVID-19, other than supportive care and dexamethasone [22].

Moreover, even less is known about how patients with pathogenic variants in type I IFN

299 pathway genes should be treated. Studying the pathways critically involved in the

pathogenesis of severe COVID-19 could lead to novel preventative and therapeutic

options to treat such patients and also their at-risk male relatives. In this respect, there

would be a strong argument to offer hemizygous TLR7 deficient males that have not had

303 COVID-19 direct access to vaccination as effective preventative measure, similar to

other patients with primary immunodeficiencies.

In summary, host genetics should be evaluated in young and apparently healthy individuals with life-threatening COVID-19. We describe two new germline putative deleterious variants in the X chromosomal *TLR7* gene. To know host DNA variants related with SARS-CoV-2 susceptibility may help physicians to identify and treat those patients at higher risk to develop severe COVID-19. In this way, their relatives at risk could be offered options for pre-symptomatic tests in order to early establish preventive measures. Further studies are needed to determine the pathogenicity of the variants reported here, as well as the prevalence of pathogenic variants in *TLR7* in larger cohorts of young, healthy male patients severely affected by SARS-CoV-2. Finally, the contribution of genetic variation in *TLR7* in the population of older healthy male

315 patients should also be assessed.

### Data availability statement

- The raw data supporting the conclusions of this article will be made available by the
- authors, without undue reservation.

#### **Ethics statement**

316

319320

327 328

336 337

338

339 340

345

- 321 Ethical approval for the study was obtained from the Hospital Universitari de Bellvitge
- 322 IDIBELL (L'Hospitalet de Llobregat, Barcelona, Spain) Research Ethics Committee
- 323 (approval number PR152/20). The patients/participants provided their written informed
- 324 consent to participate in this study. Patients from the Netherlands gave consent for
- diagnostic testing of *TLR7* and/or whole exome sequencing, patient 13 gave written
- 326 consent for publication of his clinical data.

# **Author contributions**

- 329 XS, GVP and CIvdM contributed equally to this work. XS, AH and CL devised the
- 330 study. GC, CIvdM, ARM, FS, ME and XC provided input on the study design. AA,
- BvdH, JSH, FvdV and GRB assisted in patient management. GVP, AS and JdV
- designed and performed the sequence analysis. XS, GVP, CIvdM, AH and CL had full
- access to all data and take responsibility for the integrity and the accuracy of the data.
- 334 XS, GVP, CvDM, AH and CL drafted the manuscript. All authors revised and approved
- the final manuscript.

#### **Conflicts of Interest:**

All authors declare no competing interests.

# **Acknowledgments:**

- We sincerely thank the patients and their families for their participation. With the
- 342 support of the Departament de Salut de la Generalitat de Catalunya. We thank CERCA
- Programme / Generalitat de Catalunya for institutional support. We also thank the
- Radboud Genomics Technology Center for their technical support.

# 346 **Funding:**

- Contract grant sponsor: Supported by the Carlos III National Health Institute funded by
- 348 FEDER funds a way to build Europe [PI19/00553 and CIBERONC]; and the
- 349 Government of Catalonia [2017SGR1282 and 2017SGR496]. AH is supported by the
- 350 Solve-RD project. The Solve-RD project has received funding from the European
- Union's Horizon 2020 research and innovation programme under grant agreement No.
- 352 779257. FvdV was supported by a ZonMW (The Netherlands Organization for Health
- Research and Development) Vidi grant (No. 91718351). This research was part of the
- 354 Netherlands X-omics Initiative and partially funded by NWO (The Netherlands
- Organization for Scientific Research; project 184.034.019).

#### **REFERENCES**

- 357 1- Siddigi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states:
- 358 A clinical-therapeutic staging proposal. J Heart Lung Transplant.
- 359 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20. PMID:
- 360 32362390; PMCID: PMC7118652.
- 361 2- Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al.
- 362 Features of severe COVID-19: A systematic review and meta-analysis. Eur J Clin
- 363 Invest. 2020 Oct;50(10):e13378. doi: 10.1111/eci.13378. Epub 2020 Aug 29. PMID:
- 364 32860457; PMCID: PMC7435565.
- 365 3- Rubio-Rivas M, Corbella X, Mora-Luján JM, Loureiro-Amigo J, López Sampalo A,
- 366 Yera Bergua C, et al. Predicting Clinical Outcome with Phenotypic Clusters in
- 367 COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the
- 368 Spanish Registry SEMI-COVID-19. J Clin Med. 2020 Oct 29;9(11):E3488. doi:
- 369 10.3390/jcm9113488. PMID: 33137919.
- 370 4- Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors
- 371 associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease
- 372 severity. Hum Genomics. 2020 Oct 22;14(1):40. doi: 10.1186/s40246-020-00290-4.
- 373 PMID: 33092637; PMCID: PMC7578581.
- 374 5- Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al.
- Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N 375
- Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 376
- 377 2020 Jun 17. PMID: 32558485; PMCID: PMC7315890.
- 378 6- Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO
- 379 Blood Group and the COVID-19 Susceptibility. Clin Infect Dis. 2020 Aug
- 380 4:ciaa1150. doi: 10.1093/cid/ciaa1150. Epub ahead of print. PMID: 32750119;
- 381 PMCID: PMC7454371.
- 382 7- Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and
- 383 clinical characteristics in patients with COVID-19. Clin Chim Acta. 2020
- 384 Oct;509:220-223. doi: 10.1016/j.cca.2020.06.026. Epub 2020 Jun 17. PMID:
- 385 32562665.
- 386 8- Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into
- 387 genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism
- analysis. BMC Med. 2020 Jul 15;18(1):216. doi: 10.1186/s12916-020-01673-z. 388
- 389 PMID: 32664879; PMCID: PMC7360473.
- 390 9- Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, et al. Human
- 391 Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome
- 392 Coronavirus 2. J Virol. 2020 Jun 16;94(13):e00510-20. doi: 10.1128/JVI.00510-20.
- 393 PMID: 32303592; PMCID: PMC7307149.
- 394 10- Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4
- 395 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J
- 396 Sci Med Sci. 2020 Oct 15;75(11):2231-2232.
- 397 10.1093/gerona/glaa131. PMID: 32451547; PMCID: PMC7314139.
- 398 11-Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.
- 399 Breadth of concomitant immune responses prior to patient recovery: a case report of

- 400 non-severe COVID-19. Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-
- 401 020-0819-2. PMID: 32284614; PMCID: PMC7095036.
- 402 12-Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors
- of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020
- 404 Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
- 405 PMID: 32972995.
- 406 13-van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T,
- 407 Kersten S, et al. Presence of Genetic Variants Among Young Men With Severe
- 408 COVID-19. JAMA. 2020 Jul 24;324(7):1–11. doi: 10.1001/jama.2020.13719. Epub
- 409 ahead of print. PMID: 32706371; PMCID: PMC7382021.
- 410 14-Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
- 411 mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
- 412 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May
- 413 27. Erratum in: Nature. 2021 Feb;590(7846):E53. PMID: 32461654; PMCID:
- 414 PMC7334197.
- 415 15-Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense:
- atural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev
- 417 Immunol. 2011;29:447-91. doi: 10.1146/annurev-immunol-030409-101335. PMID:
- 418 21219179.
- 419 16-Plenge RM. Molecular Underpinnings of Severe Coronavirus Disease 2019. JAMA.
- 420 2020 Jul 24. doi: 10.1001/jama.2020.14015. Epub ahead of print. PMID: 32706364.
- 421 17-Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how
- biological sex impacts immune responses and COVID-19 outcomes. Nat Rev
- 423 Immunol. 2020 Jul;20(7):442-447. doi: 10.1038/s41577-020-0348-8. Epub 2020 Jun
- 424 11. PMID: 32528136; PMCID: PMC7288618.
- 425 18-Pérez-López FR, Chedraui P, Fernández-Alonso AM. Vitamin D and aging: beyond
- 426 calcium and bone metabolism. Maturitas. 2011 May;69(1):27-36. doi:
- 427 10.1016/j.maturitas.2011.02.014. Epub 2011 Mar 22. PMID: 21429678.
- 428 19-Alvarez-Rodriguez L, Lopez-Hoyos M, Garcia-Unzueta M, Amado JA, Cacho PM,
- 429 Martinez-Taboada VM. Age and low levels of circulating vitamin D are associated
- with impaired innate immune function. J Leukoc Biol. 2012 May;91(5):829-38. doi:
- 431 10.1189/jlb.1011523. Epub 2012 Feb 17. PMID: 22345707.
- 432 20-Breidenbach JD, Dube P, Ghosh S, Abdullah BN, Modyanov NN, Malhotra D, et al.
- Impact of Comorbidities on SARS-CoV-2 Viral Entry-Related Genes. J Pers Med.
- 434 2020 Sep 25;10(4):E146. doi: 10.3390/jpm10040146. PMID: 32992731.
- 435 21-Mboowa G, Sserwadda I, Amujal M, Namatovu N. Human Genomic Loci Important
- in Common Infectious Diseases: Role of High-Throughput Sequencing and Genome-
- 437 Wide Association Studies. Can J Infect Dis Med Microbiol. 2018 Mar
- 438 20;2018:1875217. doi: 10.1155/2018/1875217. PMID: 29755620; PMCID:
- 439 PMC5884297.
- 22-RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, et
- al. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. N
- 442 Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436. Epub
- ahead of print. PMID: 32678530; PMCID: PMC7383595.

# **Table 1. Demographic and Clinical Findings of Investigated Patients**

444 445

446 447

448

449 450

451

452

Patient	Gender	Age	Ethnicity	Comorbidities	<b>ARDS</b> <sup>b</sup>	ICU	<b>ECMO</b>
1	M	30s	Caucasian	no	yes	no	no
2	M	40s	Caucasian	no	yes	yes	no
3	M	40s	Latin	no	yes	yes	yes
4	M	40s	Caucasian	no	yes	yes	no
5	M	50s	Latin	no	yes	yes	no
6	M	40s	Caucasian	no	yes	yes	no
7	M	40s	Latin	no	yes	yes	no
8	M	30s	Latin	no	yes	yes	no
9	M	40s	Latin	no	yes	no	no
10	M	30s	Latin	no	yes	yes	no
11	M	20s	Caucasian	no	yes	yes	no
12	M	30s	Caucasian	Overweight	yes	yes	no
				(BMI 28) <sup>a</sup>			
13	M	20s	Caucasian	no	yes	yes	no

Abbreviations: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; F, female; M, male; Y, years.

<sup>a</sup>Overweight was defined as a Body Mass Index greater than or equal to 25

<sup>b</sup>ARDS Definition Task Force. Acute Respiratory Distress Syndrome - The Berlin Definition. JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669.

#### Table 2. Demographic, clinical, laboratory, and radiological findings of investigated patients 453 454

454	1	T	T	1	T
	Patient 10	Patient 10 –	Patient 10 –	Patient 13	Reference
		First-degree	First-degree		ranges
Domo granhia abaya atawistias		relative	relative		
Demographic characteristics	30s	20s	60s	20s	
Age, decade Sex	Male	Male	Female	Male	
Medical history	None	None	Obesity,	Vasovagal	
Wedicar instory	None	None	dyslipidemia,	syncope	
			hypertension,	булооро	
			type 2 diabetes,		
Clinical characteristics at presentati	on		type 2 diabetes,		
Time from symptom onset to hospitalization, d	7	6	12	2	
Symptoms at disease onset	Dyspnea, cough,	Dyspnea, cough,	Dyspnea, cough,	Dyspnea,	
Symptoms at disease onset	fever, myalgia	fever, headache	fever, myalgia	cough, fever,	
	le ver, my angra	10 (01) Houdanie	io voi, iiij aigia	respiratory	
				arrest	
Imaging features (CT scan)	Bilateral	Bilateral	Bilateral	Multiple	
imaging reactives (or seam)	pulmonary	pulmonary	pulmonary	ground glass	
	consolidations	consolidations	consolidations	opacities and	
				consolidations	
				in all lung	
				segments	
ICU admission					
Time from symptom onset to ICU admission, d	8	7	12	7	
Medical reason for ICU admission	Respiratory	Respiratory	Respiratory	Respiratory	
	insufficiency	insufficiency	insufficiency	failure,	
			,	respiratory	
				arrest,	
				resuscitation	
				at home.	
Disease severity status on admission, SOFA	3	3	4	6	
score <sup>a</sup>					
Laboratory findings at ICU admission	on	T	T	1	T
Chemistry					
Alanine aminotransferase, U/L	135	14	23.5	41	<40
Albumin, g/L	37	31	28.1	23	35 - 52
Alkaline phosphatase, U/L	131	66	84.0	222	≤ 129
Aspartate aminotransferase, U/L	92	22	73.8	37	≤ 39
Cardiac troponin, high sensitivity, ng/L	NA	7	NA	NA	≤ 13
Creatine kinase, U/L	51	35	180	NA	≤ 189
Creatinine, µmol/L	60	57	57.1	84	44-97
eGFR, mL/min/1.73 m2	>90	>90	>90	>90	>90
γ-Glutamyltransferase, U/L	243	27	34.8	263	≤ 70
Lactate dehydrogenase, U/L	381	432	1088.4	201	<250
Blood count	110	114	110	101	120 165
Hemoglobin, g/L	112	114	110	121	130 - 165
Lymphocyte count, ×10 <sup>9</sup> /L	1.8	1.47	2.19	1.64	1.3-3.4
White blood cell count, ×10 <sup>9</sup> /L	18	10.7	14.74	8.4	3.9-9.5
Platelet count, ×10 <sup>9</sup> /L	385	408	416	369	149 - 303
Coagulation	0.05	0.00	1.00	27	0.9.1.2
Activated partial thromboplastin time ratio	0.95 <250	0.98 463		37	0.8-1.2
D-dimer, ng/mL			2400 5.5	3660	<250
Fibrinogen, g/L Prothrombin time ratio	> 7 1.38	> 7		4,2 NA	2.76-4.71
Inflammatory markers	1.38	1.32	1.10	NA	0.8-1.2
C-reactive protein, mg/L	346.6	267	203.98	106	~2
C-reactive protein, mg/L	340.0	207	203.98	196	<3

Ferritin, µg/L	1957.6	920	384.9	845	30 - 400
Procalcitonin, μg/L	0.28	NA	0.1	4.31	< 0.5
IL-6, ng/L	48.4	1.5	24	NA	≤ 6.9
Secondary complications	None reported	catheter-related bloodstream infection	None reported	Small ventral pneumothorax at admission after resuscitation at home. Bilateral	
Duration of viral shedding after COVID-19 onset	Positive at	Positive at	Positive at	subsegmental pulmonary embolisms.	
(positive SARS-CoV-2 PCR), d	admission, no follow-up measurement	admission, no follow-up measurement	admission, no follow-up measurement	before admission, PCR negative at day 29	
Duration of ventilatory support, d	4	10	7	24 days (ongoing)	
Duration of ICU stay, d	6	12	16	24 days (ongoing)	
Follow-up					
Time from ICU discharge to hospital discharge, d	3	11	5	NA	
Complications during follow-up period	None reported	None reported	None reported	NA	
Treatments	R, D	H, L/R, MP, I, T	R, D, T	D	

455 456 Abbreviations: COVID-19, coronavirus disease 2019; CT, computed tomography; ICU, intensive care unit; eGFR, 457 estimated glomerular filtration rate; NA, not assessed; PCR, polymerase chain reaction; SARS-CoV-2; severe acute 458 respiratory syndrome coronavirus 2; SOFA, Sequential Organ Failure Assessment. The treatments were administered to 459 the 3 patients as follows: D, Dexamethasone 6 mg / day intravenously for 10 days; R, Remdesivir 200mg orally the first 460 day and 100mg every day the next 4 days; T, Tocilizumab 600 mg single dose intravenously; L/R, Lopinavir 461 400mg/Ritonavir 100mg orally every 12 hours for 3d; H, Hydroxychloroquine orally 400mg every 12 hours the first 462 day and 200mg every 12 hours the next 10 days; I, Interferon β1b 0.25mg every 48 hours subcutaneously for 3 days. 463

<sup>a</sup> The SOFA score is calculated using 6 systems: respiratory, coagulation, hepatic, cardiovascular, central nervous, and kidney. Scores range from 0 for normal function to 4 for most abnormal and are summed for a final range of 0 to 24. An initial score of 2 to 3 is associated with 6 % mortality; an initial score of 4 to 5 is associated with 20 % mortality.




Figure 1. Schematic representation of TLR7 variants reported to date in severely affected COVID-19 cases. Variants in cDNA (top) and protein (bottom). Color code: orange, variants found in the present series; blue, previously reported in van der Made, 2020; black, previously reported in Fallerini, 2020. Shape code: circle, missense variants; square, frameshift variants. Line code: single, reported in one case; double, reported in 2 cases.

469 470

471

472